| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.12 | 3e-05 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.22 | 3e-05 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-05 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.11 | 8e-05 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0005 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.15 | 0.0009 |
| mRNA | AP-24534 | FIMM | pan-cancer | AAC | 0.52 | 0.0009 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.14 | 0.003 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.094 | 0.003 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | 0.078 | 0.004 |